Replies to post #109979 on Biotech Values

[10nisman]

If tLovenox is actually Lupenox, Teva is sailing very close to the wind of materially misleading investors as to its approvability, I would think.

Teva management maybe sailing very close to the wind however since tLovenox would never be material to Teva's results there is very little Teva investors can do but sell their shares (which seems to be happening even with Teva announcing a $1 billion buy-back). Hopefully the Sandoz/MNTA's lawsuit will help shed some light on the matter.

10nis